Published in Biotechnol Bioeng on March 20, 2004
Strategies for the recovery of active proteins through refolding of bacterial inclusion body proteins. Microb Cell Fact (2004) 1.64
Isolation of cell-free bacterial inclusion bodies. Microb Cell Fact (2010) 1.05
Growth factor delivery: how surface interactions modulate release in vitro and in vivo. Adv Drug Deliv Rev (2012) 0.93
Protein recovery from inclusion bodies of Escherichia coli using mild solubilization process. Microb Cell Fact (2015) 0.90
Expression of active hBMP2 in transgenic tobacco plants. Plant Cell Rep (2006) 0.80
Sequence-specific binding of recombinant Zbed4 to DNA: insights into Zbed4 participation in gene transcription and its association with other proteins. PLoS One (2012) 0.80
Formulation, Delivery and Stability of Bone Morphogenetic Proteins for Effective Bone Regeneration. Pharm Res (2017) 0.78
High-yield production, refolding and a molecular modelling of the catalytic module of (1,3)-beta-D-glucan (curdlan) synthase from Agrobacterium sp. Glycoconj J (2010) 0.77
MB109 as bioactive human bone morphogenetic protein-9 refolded and purified from E. coli inclusion bodies. Microb Cell Fact (2014) 0.76
Genome sequencing and analysis of the versatile cell factory Aspergillus niger CBS 513.88. Nat Biotechnol (2007) 6.21
Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview. Microb Cell Fact (2008) 1.89
Stress induced by recombinant protein production in Escherichia coli. Adv Biochem Eng Biotechnol (2004) 1.69
Strategies for the recovery of active proteins through refolding of bacterial inclusion body proteins. Microb Cell Fact (2004) 1.64
Metabolic flux analysis of Escherichia coli in glucose-limited continuous culture. I. Growth-rate-dependent metabolic efficiency at steady state. Microbiology (2005) 1.42
Preparation of bioactive soluble human leukemia inhibitory factor from recombinant Escherichia coli using thioredoxin as fusion partner. Protein Expr Purif (2010) 1.22
The intra- and extracellular proteome of Aspergillus niger growing on defined medium with xylose or maltose as carbon substrate. Microb Cell Fact (2010) 1.10
Metabolic flux analysis of Escherichia coli in glucose-limited continuous culture. II. Dynamic response to famine and feast, activation of the methylglyoxal pathway and oscillatory behaviour. Microbiology (2005) 1.08
Renaturation and purification of bone morphogenetic protein-2 produced as inclusion bodies in high-cell-density cultures of recombinant Escherichia coli. J Biotechnol (2002) 1.02
Side effects of chaperone gene co-expression in recombinant protein production. Microb Cell Fact (2010) 1.01
Simple defined autoinduction medium for high-level recombinant protein production using T7-based Escherichia coli expression systems. Appl Microbiol Biotechnol (2011) 0.99
Metabolic peculiarities of Aspergillus niger disclosed by comparative metabolic genomics. Genome Biol (2007) 0.99
Metabolic adaptation of Escherichia coli during temperature-induced recombinant protein production: 1. Readjustment of metabolic enzyme synthesis. Biotechnol Bioeng (2002) 0.99
The effect of an rhBMP-2 absorbable collagen sponge-targeted system on bone formation in vivo. Biomaterials (2009) 0.98
Application of simple fed-batch technique to high-level secretory production of insulin precursor using Pichia pastoris with subsequent purification and conversion to human insulin. Microb Cell Fact (2010) 0.97
Virus-like particle production with yeast: ultrastructural and immunocytochemical insights into Pichia pastoris producing high levels of the hepatitis B surface antigen. Microb Cell Fact (2011) 0.96
Opposing roles of Akt and STAT3 in the protection of the maternal heart from peripartum stress. Cardiovasc Res (2014) 0.95
Response of fluxome and metabolome to temperature-induced recombinant protein synthesis in Escherichia coli. J Biotechnol (2007) 0.95
Metabolic adaptation of Escherichia coli during temperature-induced recombinant protein production: 2. Redirection of metabolic fluxes. Biotechnol Bioeng (2002) 0.92
In-depth analysis of the Aspergillus niger glucoamylase (glaA) promoter performance using high-throughput screening and controlled bioreactor cultivation techniques. J Biotechnol (2008) 0.91
Metabolic costs of amino acid and protein production in Escherichia coli. Biotechnol J (2013) 0.91
Physiological response of Pichia pastoris GS115 to methanol-induced high level production of the Hepatitis B surface antigen: catabolic adaptation, stress responses, and autophagic processes. Microb Cell Fact (2012) 0.91
Simple high-cell density fed-batch technique for high-level recombinant protein production with Pichia pastoris: Application to intracellular production of Hepatitis B surface antigen. Microb Cell Fact (2009) 0.91
Functional inclusion bodies produced in bacteria as naturally occurring nanopills for advanced cell therapies. Adv Mater (2012) 0.89
More than just a metabolic regulator--elucidation and validation of new targets of PdhR in Escherichia coli. BMC Syst Biol (2011) 0.88
Roles of heat-shock chaperones in the production of recombinant proteins in Escherichia coli. Adv Biochem Eng Biotechnol (2004) 0.87
Packaging protein drugs as bacterial inclusion bodies for therapeutic applications. Microb Cell Fact (2012) 0.86
Purification of hepatitis B surface antigen virus-like particles from recombinant Pichia pastoris and in vivo analysis of their immunogenic properties. J Chromatogr B Analyt Technol Biomed Life Sci (2013) 0.85
In situ multi-wavelength fluorescence spectroscopy as effective tool to simultaneously monitor spore germination, metabolic activity and quantitative protein production in recombinant Aspergillus niger fed-batch cultures. J Biotechnol (2007) 0.84
Optimized procedure to generate heavy isotope and selenomethionine-labeled proteins for structure determination using Escherichia coli-based expression systems. Appl Microbiol Biotechnol (2011) 0.83
Application of an SPR-based receptor assay for the determination of biologically active recombinant bone morphogenetic protein-2. Anal Bioanal Chem (2005) 0.80
Folding and dimerization kinetics of bone morphogenetic protein-2, a member of the transforming growth factor-β family. FEBS J (2012) 0.80
Supramolecular organization of protein-releasing functional amyloids solved in bacterial inclusion bodies. Acta Biomater (2012) 0.80
A nanostructured bacterial bioscaffold for the sustained bottom-up delivery of protein drugs. Nanomedicine (Lond) (2013) 0.79
Conformational and functional variants of CD44-targeted protein nanoparticles bio-produced in bacteria. Biofabrication (2016) 0.76
Expression and purification of bioactive soluble murine stem cell factor from recombinant Escherichia coli using thioredoxin as fusion partner. J Biotechnol (2011) 0.76
Inclusion bodies of fuculose-1-phosphate aldolase as stable and reusable biocatalysts. Biotechnol Prog (2012) 0.76
Recombinant protein purification using gradient-assisted simulated moving bed hydrophobic interaction chromatography. Part I: selection of chromatographic system and estimation of adsorption isotherms. J Chromatogr A (2011) 0.76
Dengue-specific subviral nanoparticles: design, creation and characterization. J Nanobiotechnology (2013) 0.75
Recombinant protein purification using gradient assisted simulated moving bed hydrophobic interaction chromatography. Part II: process design and experimental validation. J Chromatogr A (2011) 0.75
Discontinuous and continuous separation of the monomeric and dimeric forms of human bone morphogenetic protein-2 from renaturation batches. J Chromatogr A (2006) 0.75
Kinetics control preferential heterodimer formation of platelet-derived growth factor from unfolded A- and B-chains. J Biol Chem (2003) 0.75
Step gradients in 3-zone simulated moving bed chromatography. Application to the purification of antibodies and bone morphogenetic protein-2. J Chromatogr A (2007) 0.75
Change of extracellular cAMP concentration is a sensitive reporter for bacterial fitness in high-cell-density cultures of Escherichia coli. Biotechnol Bioeng (2004) 0.75